LyseNTech is licensed to use phages from the Bacteriophage Bank of Korea. The company develops bacteriophage and endolysin therapeutics against Multidrug-resistant (MDR) pathogens. It also develops bacteriophages as gene delivery vehicles to serve as anticancer therapy, gene therapy, and vaccine platforms. LyseNTech provides the service of phage matching to specific pathogens, upon request.
Currently, two endolysins targeting Gram-negative bacteria are in the preclinical stage. One phage cocktail targeting Adherent-invasive Escherichia coli (AIEC) is in the lead optimization stage.
Bacteriophage product pipeline:
- LNT PT101 – target: Adherent-invasive Escherichia coli (AIEC) for IBD patients
- LNT PT201 – Engineered phage oncolytic phage for cancer treatment
Bacteriophage-based product pipeline:
- LNT104 – Engineered endolysin targeting systemic infection caused by Acinetobacter baumannii
- LNT113 – Engineered endolysin targeting Gram-negative bacterial infection for Diabetic Foot Ulcer